Extended Data Fig. 6: Systemic administration of ML-SA1 in HFD-LOH mice.
From: Targeting dysregulated phago-/auto-lysosomes in Sertoli cells to ameliorate late-onset hypogonadism
a, Body weight of HFD-LOH mice with daily ML-SA1 treatment and TRT (nVehicle, ML-SA1 = 6 mice, nTestosterone = 5). b, Representative mouse testis and the ratio of testis weight to body weight in HFD-LOH mice with ML-SA1 treatment and TRT (nVehicle, ML-SA1 = 12, nTestosterone = 10). c, d, Representative staining and quantification of PPT1(c) and NileRed (d) in testis of HFD-LOH mice with ML-SA1 treatment and TRT(c, nND = 200 cells, nVehicle = 326, nML-SA1=236, nTestosterone = 232; d, nND = 211 cells, nVehicle = 215, nML-SA1=216, nTestosterone = 199). e, DEG of SCs in ND and HFD treated with Vehicle or ML-SA1. f, GO analysis of ML-SA1 treatment effect on DEG of SCs between HFD vs ND. g, DEG of LCs in ND and HFD treated with Vehicle or ML-SA1. h, GO analysis of ML-SA1 treatment effect on DEG of LCs between HFD vs ND. At least five individual mice for each group. The boxes represent the median and interquartile range and the bars represent roughly 95% confidence interval for comparing medians (c). Data are presented as mean ± s.e.m (a, b). Comparison by two-tailed unpaired t-test.
